As an effort for international cancer proteogenomics consortia (ICPC) initiative, we are charactering the molecular changes among never-smoking lung cancer patients (up to 150) without known driver genes such as EGFR, KRAS, and ALK fusions. Until now, we have generated the whole genome, transcriptome, DNA methylome, proteome, and immune cell profiling of 116 Korean never-smoking lung cancer tissues selected from screening more than 1000 lung cancer tissues. Most never-smoking lung cancer patients showed lower mutation burden (2.6/Mb) than smoking lung cancer patients (11.8-14.4/Mb from TCGA data) except for a few patients (194/Mb) with POLE and POLD1 mutations or mismatch repair defects. We identified several significantly mutated genes among the 116 patients. Transcriptome analysis revealed three sub-groups which showed significant differences in the mutation burdens. We are currently performing integration of multi-genomics and proteomics data and continue to generate multi-omics data for more never-smoking ling cancer patients.
Grant support: NRF-2017M3A9F9030559 (to C Lee), NRF-2017M3A9F9030565 (to KC Park), and NRF-2017M3A9F9030648 (to JY Han)